{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T17:59:06Z","timestamp":1781373546983,"version":"3.54.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1007\/s40265-015-0460-4","type":"journal-article","created":{"date-parts":[[2015,8,31]],"date-time":"2015-08-31T06:23:45Z","timestamp":1441002225000},"page":"1567-1573","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Evolocumab: First Global Approval"],"prefix":"10.1007","volume":"75","author":[{"given":"Anthony","family":"Markham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,1]]},"reference":[{"key":"460_CR1","unstructured":"European Medicines Agency. Repatha (evolocumab): EU summary of product characteristics. 2014. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003766\/WC500191398.pdf . Accessed 4 Aug 2015."},{"key":"460_CR2","unstructured":"Amgen, Astellas Pharma. Amgen and Astellas announce Japan alliance [media release]. 29 May 2013. http:\/\/www.amgen.com ."},{"issue":"19","key":"460_CR3","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.jacc.2012.08.986","volume":"60","author":"CS Dias","year":"2012","unstructured":"Dias CS, Shaywitz AJ, Wasserman SM, et al. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol. 2012;60(19):1888\u201398.","journal-title":"J Am Coll Cardiol."},{"key":"460_CR4","first-page":"S69","volume":"97","author":"MG Emery","year":"2015","unstructured":"Emery MG, Gibbs JP, Slatter JG, et al. Evolocumab pharmacokinetics and its effects on LDL-C and PCSK9 lowering in subjects with mild or moderate hepatic impairment [abstract no. PII-034]. Clin Pharmacol Ther. 2015;97:S69.","journal-title":"Clin Pharmacol Ther."},{"key":"460_CR5","doi-asserted-by":"crossref","unstructured":"Gibbs JP, Grover A, Emery MG, et al. Impact of target-mediated elimination on evolocumab dose and regimen [abstract no. 422]. In: European Atherosclerosis Society Annual Congress 2015. 2015.","DOI":"10.1016\/j.atherosclerosis.2015.04.956"},{"issue":"Suppl 2","key":"460_CR6","first-page":"A16270","volume":"130","author":"SM Wasserman","year":"2014","unstructured":"Wasserman SM, Koren MJ, Giugliano RP, et al. Evaluation of the relationship between evolocumab 140\u00a0mg every two weeks and 420\u00a0mg monthly dosing regimens [abstract no. 16270]. Circulation. 2014;130(Suppl 2):A16270.","journal-title":"Circulation."},{"issue":"10","key":"460_CR7","doi-asserted-by":"crossref","first-page":"A1368","DOI":"10.1016\/S0735-1097(15)61368-7","volume":"65","author":"EA Stein","year":"2015","unstructured":"Stein EA, Koren M, Honarpour N, et al. Clinical equivalence of evolocumab 140\u00a0mg every two weeks and 420\u00a0mg monthly dosing regimens: a pooled analysis of 3146 patients in phase 3 studies. J Am Coll Cardiol. 2015;65(10):A1368.","journal-title":"J Am Coll Cardiol."},{"issue":"19","key":"460_CR8","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","volume":"370","author":"DJ Blom","year":"2014","unstructured":"Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370(19):1809\u201319.","journal-title":"N Engl J Med."},{"issue":"18","key":"460_CR9","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.2014.4030","volume":"311","author":"JG Robinson","year":"2014","unstructured":"Robinson JG, Nedergaard BS, Rogers WJ, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014;311(18):1870\u201382.","journal-title":"JAMA."},{"issue":"10","key":"460_CR10","doi-asserted-by":"crossref","first-page":"A1369","DOI":"10.1016\/S0735-1097(15)61369-9","volume":"65","author":"A Kiyosue","year":"2015","unstructured":"Kiyosue A, Honarpour N, Xue A, et al. Effects of evolocumab (AMG 145) in hypercholesterolemic, statin-treated, Japanese patients at high cardiovascular risk: Results from the phase III yukawa 2 study. J Am Coll Cardiol. 2015;65(10):A1369.","journal-title":"J Am Coll Cardiol."},{"issue":"9858","key":"460_CR11","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","volume":"380","author":"RP Giugliano","year":"2012","unstructured":"Giugliano RP, Desai NR, Kohli P, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet. 2012;380(9858):2007\u201317.","journal-title":"Lancet."},{"issue":"23","key":"460_CR12","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","volume":"63","author":"E Stroes","year":"2014","unstructured":"Stroes E, Colquhoun D, Sullivan D, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014;63(23):2541\u20138.","journal-title":"J Am Coll Cardiol."},{"issue":"23","key":"460_CR13","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2012.25790","volume":"308","author":"D Sullivan","year":"2012","unstructured":"Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA. 2012;308(23):2497\u2013506.","journal-title":"JAMA."},{"issue":"23","key":"460_CR14","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","volume":"63","author":"MJ Koren","year":"2014","unstructured":"Koren MJ, Lundqvist P, Bolognese M, et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol. 2014;63(23):2531\u201340.","journal-title":"J Am Coll Cardiol."},{"issue":"9858","key":"460_CR15","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(12)61771-1","volume":"380","author":"MJ Koren","year":"2012","unstructured":"Koren MJ, Scott R, Kim JB, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2012;380(9858):1995\u20132006.","journal-title":"Lancet."},{"issue":"9965","key":"460_CR16","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","volume":"385","author":"FJ Raal","year":"2015","unstructured":"Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9965):331\u201340.","journal-title":"Lancet."},{"issue":"9965","key":"460_CR17","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","volume":"385","author":"FJ Raal","year":"2015","unstructured":"Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9965):341\u201350.","journal-title":"Lancet."},{"key":"460_CR18","doi-asserted-by":"crossref","unstructured":"Raal F, Hovingh K, Blom D, et al. Long-term treatment with evolocumab in patients with homozygous familial hypercholesterolaemia (HoFH): interim results from the trial assessing long-term use of PCSK9 inhibition in subjects with genetic LDL disorders (TAUSSIG) study [abstract no. 1042]. In: 17th International Symposium on Atherosclerosis. 2015.","DOI":"10.1016\/j.atherosclerosis.2016.07.221"},{"issue":"20","key":"460_CR19","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","volume":"126","author":"F Raal","year":"2012","unstructured":"Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation. 2012;126(20):2408\u201317.","journal-title":"Circulation."},{"issue":"19","key":"460_CR20","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1161\/CIRCULATIONAHA.113.004678","volume":"128","author":"EA Stein","year":"2013","unstructured":"Stein EA, Honarpour N, Wasserman SM, et al. Effect of the proprotein convertase subtilisin\/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation. 2013;128(19):2113\u201320.","journal-title":"Circulation."},{"issue":"10","key":"460_CR21","doi-asserted-by":"crossref","first-page":"A1351","DOI":"10.1016\/S0735-1097(15)61351-1","volume":"65","author":"PP Toth","year":"2015","unstructured":"Toth PP, Sattar N, Genest J, et al. A comprehensive safety analysis of 6026 patients from phase 2 and 3 short and long term clinical trials with evolocumab (AMG 145). J Am Coll Cardiol. 2015;65(10):A1351.","journal-title":"J Am Coll Cardiol."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0460-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-015-0460-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0460-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T00:54:18Z","timestamp":1567126458000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-015-0460-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":21,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["460"],"URL":"https:\/\/doi.org\/10.1007\/s40265-015-0460-4","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9]]}}}